⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18778719 | 0.92 | CRBN (0.39) | — | |
| Water SCHEMBL27533110 | 0.81 | — | — | |
| SCHEMBL22010381 | 0.75 | — | — | |
| SCHEMBL967374 | 0.72 | — | — | |
| SCHEMBL17408821 | 0.72 | — | — | |
| SCHEMBL13944676 | 0.65 | OR51E2 (0.33) | — | |
| SCHEMBL22010631 | 0.65 | — | — | |
| SCHEMBL25827383 | 0.64 | — | — | |
| SCHEMBL16605686 | 0.64 | CRBN (0.35) | — | |
| SCHEMBL21530565 | 0.63 | MAPT (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3177614-B1 | FUSED BICYCLIC ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2022-02-23 | — | — | EP | disclosed |
| EP-3177287-B1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2022-02-23 | — | — | EP | disclosed |
| US-11072602-B2 | Antidiabetic heterocyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2021-07-27 | — | — | US | disclosed |
| US-10968232-B2 | Antidiabetic spirochroman compounds | MERCK SHARP & DOHME CORP. (US) | 2021-04-06 | — | — | US | disclosed |
| US-10968193-B2 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2021-04-06 | — | — | US | disclosed |
| US-10662171-B2 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2020-05-26 | — | — | US | disclosed |
| US-10290900-B2 | Non-aqueous electrolytic solution and lithium ion secondary battery comprising same | NIPPON SHOKUBAI CO., LTD. (JP) | 2019-05-14 | — | — | US | disclosed |
| WO-2018118670-A1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018106518-A1 | ANTIDIABETIC HETEROCYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2018-06-14 | — | — | WO | disclosed |
| US-9977024-B2 | Targeted covalent probes and inhibitors of proteins containing redox-sensitive cysteines | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-05-22 | — | — | US | disclosed |
| US-7534787-B2 | Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-19 | — | — | US | disclosed |
| US-20090099159-A1 | Method of Treating Diseases and Conditions Associated with an Altered Level of Amyloid Beta Peptides and New Enolcarboxamide Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20080194617-A1 | Fused ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
| US-7393843-B2 | Method of treating diseases and conditions associated with an altered level of amyloid β peptides and new enolcarboxamide compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-01 | — | — | US | disclosed |
| US-20080139541-A1 | Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds | BORNEMANN KLAUS | 2008-06-12 | — | — | US | disclosed |
| US-7375220-B2 | Method of treating diseases and conditions associated with an altered level of amyloid β peptides and new enolcarboxamide compounds | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2008-05-20 | — | — | US | disclosed |
| EP-1750719-A2 | TREATMENT OF DISEASES ASSOCIATED WITH ALTERED LEVEL OF AMYLOID BETA PEPTIDES | Boehringer Ingelheim International GmbH (DE) | 2007-02-14 | — | — | EP | disclosed |
| US-20060040928-A1 | Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2006-02-23 | — | — | US | disclosed |
| US-20050277635-A1 | Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-15 | — | — | US | disclosed |
| WO-2005110422-A2 | TREATMENT OF DISEASES ASSOCIATED WITH ALTERED LEVEL OF AMYLOID BETA PEPTIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |